Navigation Links
Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
Date:1/27/2008

d LV with oxaliplatin) after three months of therapy or sooner if significant (Grade 3 or greater) neurotoxicity develops. For more information, please see http://www.nccn.org.

In the Phase 1 study, 50 patients were treated with picoplatin on either an every-two-week or an every-four-week basis in combination with the standard of care every-two-week dose of 5FU and LV. Patients received up to 28 cycles, and the therapy was well tolerated. Increased hematological toxicity was observed at higher doses. None of the patients treated with picoplatin exhibited a Grade 3 or higher neuropathy and only 9 of 45 patients (20 percent) experienced mild neuropathy. No neuropathy of Grade 2 or greater was observed in the 26 patients who received greater than or equal to 400 mg/m squared picoplatin. Mild nephro- and oto- toxicity were observed infrequently. The dose limiting toxicity (DLT) was most frequently hematological with neutropenia and thrombocytopenia. The maximum tolerated dose was established in the every-four-week schedule at 150 mg/m squared. The maximum tolerated dose for the every-two-week schedule has not yet been reached.

Based on the evidence of a more attractive safety profile of picoplatin in this combination (FOLPI) compared to the standard of care regimen with oxaliplatin (FOLFOX) as well as clinical activity in the Phase 1 study, the Company initiated a randomized Phase 2 trial in November, 2007 to evaluate intravenous picoplatin in the first-line treatment of mCRC. The Phase 2 trial is intended to generate proof-of-concept data to further evaluate efficacy and safety, including neuropathy of picoplatin in combination with 5-FU and LV (FOLPI versus FOLFOX) and to provide support for a potential registrational Phase 3 trial. The Company expects to present data from the Phase 1 and 2 mCRC program in scientific forums around mid year.

About Picoplatin

Picoplatin is an intravenous chemoth
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
2. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
5. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
9. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... robust development with the growth pace keeping at 20%-30% in ... the size of China separating membrane ... to 16.3%. It is projected that China ... around 20% in the upcoming years and that the figure ... An integrated membrane industrial system has taken shape in ...
(Date:12/17/2014)... 17, 2014  Northstar Global Business Services, Inc. ... (DTC) has made their final decision and has ... Company,s stock effective December 15, 2014, and has ... depository and book entry transfer services. All deposit restrictions ... once again fully "DTC Eligible", and has resumed ...
(Date:12/17/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or the ... $125 million aggregate principal amount of 3.75% Convertible Senior ... and sold only to qualified institutional buyers pursuant to ... amended (the "Securities Act"). The Notes bear ... payable semiannually in arrears on June 15 and December ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... READING, England , June 25, 2010 ... announced that its,lead product, PecFent*, has received a Positive ... the European Medicines Agency (EMA).,The CHMP is recommending PecFent, ... European Union countries for the treatment of,breakthrough cancer pain ...
... 24 Reportlinker.com announces that a new market research report is available in ... Global Medical Device Outsourcing Industry ... http://www.reportlinker.com/p0209279/Global-Medical-Device-Outsourcing-Industry.html , ... This report analyzes the Global market for Medical Devices Outsourcing in US$ ...
Cached Medicine Technology:Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain 2Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain 3Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain 4Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain 5Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain 6Reportlinker Adds Global Medical Device Outsourcing Industry 2Reportlinker Adds Global Medical Device Outsourcing Industry 3Reportlinker Adds Global Medical Device Outsourcing Industry 4Reportlinker Adds Global Medical Device Outsourcing Industry 5Reportlinker Adds Global Medical Device Outsourcing Industry 6Reportlinker Adds Global Medical Device Outsourcing Industry 7
(Date:12/19/2014)... TX (PRWEB) December 19, 2014 ... a shifting, capital equipment market that is saturated ... impressive safety and efficacy as well as non-invasive ... they were first introduced to the healthcare market. ... the development of MRI safe technologies have greatly ...
(Date:12/19/2014)... From November 24, 2014, Siddhi Yoga ... 2014 in its Goa retreat . This is the ... winters, from November to March, Siddhi Yoga will organize four ... Goa. The Goa training sessions will conclude in March 2015. ... training, the 10th intake is also a 200 YTT ...
(Date:12/19/2014)... Wilmington, VT (PRWEB) December 19, 2014 ... full-service private ski club in Southern Vermont’s Deerfield Valley, ... trail names inspired by classic rock songs. , ... the weekend with a private concert followed by a ... said, “The new trail names include: “I’m Alright” the ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, ... ibuprofen, might slightly reduce your risk of developing a ... ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to reduce ... percent, the researchers concluded after reviewing nine prior studies. ... exposure. These painkillers "have potential as ...
(Date:12/17/2014)... 17, 2014 Dr. Myo Nwe is the ... Diet of the Future” and co-founder of the Ace Medical ... Dr. Nwe takes a broad look at the industry of ... under scientific scrutiny. On film and in television shows, however, ... toward the social aspects and played for basic laughs, which ...
Breaking Medicine News(10 mins):Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 3Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2
... ... heart function without need for cardiac stem cells , ... (Vocus) July 16, 2009 -- Injured heart tissue normally can,t regrow, ... heart tissue after a heart attack, in patients with heart failure, or in children with ...
... coronary function are restored , THURSDAY, JULY 23 (HealthDay ... tissue renew itself after a heart attack -- until now. ... to the heart become blocked, preventing enough oxygen from getting ... But researchers at Children,s Hospital Boston report progress toward someday ...
... , , PIPERSVILLE, Pa., July 23 ... the body,s mechanism for cooling itself is overactive and can cause ... than normal. While some people may only think about sweating during ... can disrupt their daily and recreational activities, regardless of the season. ...
... , ROANOKE, Va., July 23 Job ... The Virginia Psychological Association (VPA) and Virginia Academy of Clinical ... this cost by awarding the 2009 VPA/VACP Psychologically Healthy Workplace ... submit nominations. , , ...
... , , LOS ANGELES, July 23 ... AIDS Programs and Policy is launching its most comprehensive community outreach campaign ... of those who have HIV does not know it. , ... Titled "Virus," the multi-faceted campaign is designed to raise doubt ...
... , INDIANAPOLIS, July 23 Today, Eli ... the U.S. Food and Drug Administration (FDA) has approved a ... injection] to treat osteoporosis associated with sustained, systemic glucocorticoid therapy ... therapy is the most common cause of secondary osteoporosis, leading ...
Cached Medicine News:Health News:Study in this Week's Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 2Health News:Study in this Week's Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 3Health News:Injection May Heal Damaged Heart 2Health News:Photos: Don't Let Them See You Sweat This Summer 2Health News:Photos: Don't Let Them See You Sweat This Summer 3Health News:Photos: Don't Let Them See You Sweat This Summer 4Health News:Photos: Don't Let Them See You Sweat This Summer 5Health News:Los Angeles County Launches Its Most Comprehensive Campaign Ever to Encourage HIV Testing 2Health News:Los Angeles County Launches Its Most Comprehensive Campaign Ever to Encourage HIV Testing 3Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 2Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 3Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 4Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 5Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 6
... A surgically implanted bone growth stimulator ... EBI OsteoGen surgically implanted bone growth stimulator ... of nonunions when surgery is already planned ... concern. Because the OsteoGen is totally surgically ...
... contact between grant material and fracture ends ... bones., ,Grid-Like Format of Mesh Cathode Provides ... , ,The innovative Mesh Cathode of the ... and a scaffolding effect designed to increase ...
... Cystoscope System using EndoSheath Technology introduces ... urologists in both their hospitals and ... flexible cystoscope with the sterile, protective ... procedures, while minimizing the costs of ...
... Plasma-CISE™ (wire electrodes) and Plasma-CUT™ ... devices that produce precise, consistent ... spread and Vapor sealing of ... The devices provide excellent results ...
Medicine Products: